Skip to main content
Erschienen in: Diabetologia 3/2004

01.03.2004 | Short Communication

Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes

verfasst von: A. S. F. Doney, B. Fischer, J. E. Cecil, K. Boylan, F. E. McGuigan, S. H. Ralston, A. D. Morris, C. N. A. Palmer, PhD

Erschienen in: Diabetologia | Ausgabe 3/2004

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The Pro12Ala polymorphism of peroxisome proliferator-activated receptor (PPAR)γ has been consistently associated with Type 2 diabetes. The rare Ala12 variant is estimated to reduce the risk of developing Type 2 diabetes by 20 percent. This variant is in linkage disequilibrium with another common variant, T1431. Both have opposing associations with body weight. We therefore examined the association of specific haplotypes marked by these two variants with susceptibility to Type 2 diabetes.

Methods

We determined the PPARG genotype of a large Scottish cohort of Type 2 diabetic patients (n=1997) and compared allele frequencies with a cohort of local children (n=2444) and a middle-aged, population-based cohort from Scotland (n=1061).

Results

Frequency of the Ala12 allele was slightly lower in the Type 2 diabetic cohort than in the children [odds ratio (OR)=0.91, p=0.1]. In contrast, the Ala12 variant was under-represented in the Type 2 diabetic population when compared with similarly aged non-diabetic adults (OR=0.74, p=0.0006). When the Ala12 variant was on a haplotype not bearing the 1431T variant, it conferred greater protection (OR=0.66, p=0.003). However, when it was present in haplotypes containing the 1431T variant (70% of Ala12 carriers), this protection was absent (OR=0.99, p=0.94).

Conclusions/interpretation

We replicated the finding that the Ala12 variant of PPARγ affords protection from Type 2 diabetes, and suggest that this protection is modulated by additional common variation at the PPARG locus.
Literatur
1.
Zurück zum Zitat Deeb SS, Fajas L, Nemoto M, et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287CrossRefPubMed Deeb SS, Fajas L, Nemoto M, et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287CrossRefPubMed
2.
Zurück zum Zitat Luan J, Browne PO, Harding AH et al. (2001) Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50:686–689CrossRefPubMed Luan J, Browne PO, Harding AH et al. (2001) Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50:686–689CrossRefPubMed
3.
Zurück zum Zitat Doney A, Fischer B, Frew D et al. (2002) Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 3:21CrossRefPubMedPubMedCentral Doney A, Fischer B, Frew D et al. (2002) Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 3:21CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Morris AD, Boyle DI, MacAlpine R et al. (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 315:524–528CrossRefPubMedPubMedCentral Morris AD, Boyle DI, MacAlpine R et al. (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 315:524–528CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat McGuigan FE, Armbrecht G, Smith R, Felsenberg D, Reid DM, Ralston SH (2001) Prediction of osteoporotic fractures by bone densitometry and COLIA1 genotyping: a prospective, population-based study in men and women. Osteoporos Int 12:91–96CrossRefPubMed McGuigan FE, Armbrecht G, Smith R, Felsenberg D, Reid DM, Ralston SH (2001) Prediction of osteoporotic fractures by bone densitometry and COLIA1 genotyping: a prospective, population-based study in men and women. Osteoporos Int 12:91–96CrossRefPubMed
6.
Zurück zum Zitat Ek J, Andersen G, Urhammer SA et al. (2001) Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44:1170–1176CrossRefPubMed Ek J, Andersen G, Urhammer SA et al. (2001) Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44:1170–1176CrossRefPubMed
7.
Zurück zum Zitat Ardlie KG, Lunetta KL, Seielstad M (2002) Testing for population subdivision and association in four case-control studies. Am J Hum Genet 71:304–311CrossRefPubMedPubMedCentral Ardlie KG, Lunetta KL, Seielstad M (2002) Testing for population subdivision and association in four case-control studies. Am J Hum Genet 71:304–311CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Ridker PM, Cook NR, Cheng S et al. (2003) Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 23:859–863CrossRefPubMedPubMedCentral Ridker PM, Cook NR, Cheng S et al. (2003) Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 23:859–863CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Ostgren CJ, Lindblad U, Melander O, Melander A, Groop L, Rastam L (2003) Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project. J Hypertens 21:1657–1662CrossRefPubMed Ostgren CJ, Lindblad U, Melander O, Melander A, Groop L, Rastam L (2003) Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project. J Hypertens 21:1657–1662CrossRefPubMed
10.
Zurück zum Zitat Rodriguez-Esparragon FJ, Rodriguez-Perez JC, Macias-Reyes A, Alamo-Santana F (2003) Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/bgene polymorphisms are associated with essential hypertension. J Hypertens 21:1649–1655CrossRefPubMed Rodriguez-Esparragon FJ, Rodriguez-Perez JC, Macias-Reyes A, Alamo-Santana F (2003) Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/bgene polymorphisms are associated with essential hypertension. J Hypertens 21:1649–1655CrossRefPubMed
Metadaten
Titel
Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes
verfasst von
A. S. F. Doney
B. Fischer
J. E. Cecil
K. Boylan
F. E. McGuigan
S. H. Ralston
A. D. Morris
C. N. A. Palmer, PhD
Publikationsdatum
01.03.2004
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 3/2004
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1323-1

Weitere Artikel der Ausgabe 3/2004

Diabetologia 3/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.